Assembly biosciences doses first participant in phase 1b portion of phase 1a/b clinical trial of investigational long-acting herpes simplex virus helicase-primase inhibitor abi-1179

– study will evaluate safety and antiviral activity of abi-1179 in participants with recurrent genital herpes – – abi-1179 ind cleared to support study expansion to sites in united states – – phase 1b studies for abi-1179 and abi-5366 running concurrently with interim data for both candidates on track for fall 2025 – south san francisco, calif., june 30, 2025 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the phase 1b portion of the phase 1a/b study of its long-acting herpes simplex virus (hsv) helicase-primase inhibitor candidate abi-1179.
ASMB Ratings Summary
ASMB Quant Ranking